)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Diaceutics
Diaceutics (DXRX) investor relations material
Diaceutics H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary22 Sep, 2026
Executive summary
Supported 18 of the top 20 global pharma companies, serving 55 customers across 103 therapeutic brands in H1 2026.
Revenue grew 22% year-over-year on a constant currency basis to £17.5 million, with ARR up 79% to £29.4 million and order book up 38% to £43.7 million.
Strategic repositioning under "Precision For All" expanded the addressable market from 250 to over 1,100 therapies, with 22% of H1 revenue from this segment.
Relay (formerly PMx) ARR increased from £2.6 million at inception to £4.3 million at June 2026.
Board remains confident in meeting 2026 expectations.
Financial highlights
Revenue: £17.5 million (+22% constant currency), ARR: £29.4 million (+79%), order book: £43.7 million (+38%).
Gross profit: £14.9 million (+23%), gross margin: 85% (+2 ppts), Adjusted EBITDA: £1.1 million (6.1% margin), operating loss: £4.0 million.
Free cash flow: £0.7 million (improved by £3.1 million), cash at period end: £8.1 million, no debt.
Net Revenue Retention reached 149%, gross ARR churn reduced to 6%, and recurring revenue represented 61% of total revenue.
Recurring revenue in H1 grew 42% to £12.5 million.
Outlook and guidance
107% visibility on achieving FY 2026 median analyst consensus revenue estimates as of 31 August 2026.
Board expresses confidence in delivering against 2026 expectations.
H2 revenue expected to be higher, with a forecast H1:H2 split of 38:62, reflecting recurring revenue recognition.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Diaceutics
- Strong H1 2026 revenue and ARR growth drive high visibility and confidence for FY 2026 targets.DXRX
H1 2026 TU - FY 2025 saw 24% revenue growth, margin expansion, and record ARR, driven by platform and market gains.DXRXCorporate presentation
- 24% revenue growth, 80% EBITDA rise, and record order book drive strong 2026 outlook.DXRXH2 2025
- 20% revenue growth, record ARR, and strong FY 2026 outlook amid expanding partnerships.DXRXQ4 2025 TU
- Revenue up 22% to £14.6m, ARR up 16%, and positive EBITDA signal profitability on track.DXRXH1 2025
- 22% revenue growth, rising recurring revenues, and strong pipeline underpin FY 2025 confidence.DXRXTrading Update
- 24% revenue growth, 87% gross margin, and PMx launch set stage for 2025 profitability.DXRXH1 2024
- AI-powered DXRX platform drives high-margin recurring revenue and ROI in precision medicine.DXRXCME 2024
- 39% revenue growth, 88% margin, and US expansion drive 2025 profitability shift.DXRXH2 2024
Diaceutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage